

P03-127

**GALANTAMINE IN LONG-TERM TREATMENT FORMILD COGNITIVE IMPAIRMENT:
EFFICACY AND SAFETY**

J. Zarra¹, L. Schmidt², B. Grecco³

¹Psiquiatría, Hospital Italiano de La Plata, La Plata, ²Psiquiatría, Centro Médico San Lucas, Argentina, ³Neurociencias, Centro de Neurología y Psiquiatría-Psicología (CeNyPP), Gualeguaychú, Argentina

Introduction: To evaluate the efficacy of galantamine in patients with Mild Cognitive Impairment. So there is a possible benefit in the deficit in executive and cognitive cerebral function (cholinergic system) with treatment with Galantamine.

Purpose: Galantamine is a reversible, competitive cholinesterasa inhibitor that also allosterically modulates nicotine acetylcholine receptors. Inhibition of acetylcholinesterase, the enzyme responsible for hydrolisis of acetylcholine at the cholinergic cognitive impairment. To evaluate the efficacy , safety and tolerability of galantamine in long-term in Mild Cognitive Disorder.

Methods: A multicenter, open label , prospective, observational study enrolled 1028 patients, more 55 years old with Mild Neurocognitive Disorder (DSM IV criteria), during 30 months of treatment with galantamine 16 mg./day. Assessments included the MMSE, CDR, ADAS-GOG, FAQ, GCI, Trail making test, Global Deterioration Scale, and UKU scale of Adverse Effects.

Results: A total 1028 outpatients were treated with 16 mg./day galantamine during 30 months , the therapeutic response evaluated with CDR , MMSE and the tests and scales of function cognitive measuring , GCI and UKU scale of adverse effects, comparing the baseline to final scores .

Conclusion: Mild Cognitive Disorder is being examined, so there aren't enough treatment for this. A long-term treatment (30 months) galantamine improves cognition and global function, behavioural symptoms and the general state well being of patients with MCD. With incidence of adverse effects not significant and a very good profile of safety, the final results of the study suggest that galantamine may be particularly appropriate in the Mild Cognitive Disorder.